Subscribe

Spotlight -

Bahtiyar Toz, MD

Bahtiyar Toz, MD, Icahn School of Medicine, Mount Sinai

Icahn School of Medicine, Mount Sinai

Articles by Bahtiyar Toz, MD

Obinutuzumab Shows Durable Kidney Protection and High Remission Rates in Lupus Nephritis, with Bahtiyar Toz, MD

Obinutuzumab Shows Durable Kidney Protection and High Remission Rates in Lupus Nephritis, with Bahtiyar Toz, MD

ByBahtiyar Toz, MD

October 27th 2025

Obinutuzumab was approved earlier in October for LN under the name Gazyva.

Latest Updated Articles

Obinutuzumab Shows Durable Kidney Protection and High Remission Rates in Lupus Nephritis, with Bahtiyar Toz, MD
October 27th 2025

Trending on Rheumatology Live

Nipocalimab, Telitacicept, and the Sjögren’s Disease Pipeline

Dazodalibep Eases Sjögren’s Dryness via CD40L Blockade: Ghaith Noaiseh, MD

Dazodalibep Lowers Sjögren’s Disease Activity: Ghaith Noaiseh, MD

INDIGO: Obexelimab Sustains IgG4-RD Flare Control, With John Stone, MD, MPH

Selecting Sjögren’s Patients for Ianalumab and Weighing Safety